Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × Trastuzumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 520 Stomach Neoplasms 57 Neoplasm Metastasis 47 Neoplasms 35 HER2-positive Breast Cancer 29 Breast Neoplasms, Male 26 Colorectal Neoplasms 23 Brain Neoplasms 20 Esophageal Neoplasms 19 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 10 Endometrial Neoplasms 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Ovarian Neoplasms 8 Adenocarcinoma Of Esophagus 7 Adenocarcinoma 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Salivary Gland Neoplasms 6 Prostatic Neoplasms 6 Pathologic Complete Response 6 Lung Neoplasms 6 Gallbladder Neoplasms 6 Cardiotoxicity 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Breast Diseases 5

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡